JPMorgan keeps Agios Pharmaceuticals at Neutral and cuts target to $30
According to TradingView, JPMorgan kept its Neutral rating on Agios Pharmaceuticals and reduced the price target to $30 from $34, an 11.8% cut.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
TradingView reports that JPMorgan kept its Neutral recommendation on Agios Pharmaceuticals and lowered its price target to $30 from $34. The cut amounts to 11.8%. The new target implies a 4.3% upside from the November 19 closing price of $28.76.
The note covers only the analyst rating. Investors can compare the new target with the previous one and with other brokers' estimates on TradingView, where the reference data is provided by Benzinga.
why it matters
An adjustment of this size usually affects a single stock rather than the broader market. For Agios shareholders, the key reference is the gap between the new target and the last close, while the Neutral rating signals no clear preference between buying and selling.
tags
instruments
sources
- JP Morgan maintains Agios Pharmaceuticals at Neutral, lowers price target to $30 from $34 — TradingView, 20 November 2026 at 17:44 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗